Share Price | Immix Biopharma, Inc. Stock Analysis & Recommendation

Q: How big is Immix Biopharma, Inc.?

Market Cap: As of Jun 18, Immix Biopharma, Inc. has a market capitalization of 63.56 million, which classifies it as a Micro Cap company.Recent Quarterly Performance: For the latest four quarters, Immix Biopharma, Inc. reported net sales of 0.00 million and a net profit of -20.91 million.Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 13.25 million and total assets of 22.95 million.

Q: What does Immix Biopharma, Inc. do?

Overview: Immix Biopharma, Inc. operates in the Pharmaceuticals & Biotechnology industry and is categorized as a micro-cap company.Financial Snapshot: Net Profit: -5 Million (Quarterly Results - Mar 2025) Market Cap: USD 63.56 Million (Micro Cap)Key Metrics: P/E: NA (Loss Making) Industry P/E: NA Dividend Yield: 0.00% Debt Equity: -1.65 Return on Equity: -217.96% Price to Book: 6.63Contact Details: Details: No Company Details Available Registrar Address: Not available.

Q: Is Immix Biopharma, Inc. technically bullish or bearish?

As of 12 September 2025, the technical trend for Immix Biopharma, Inc. has changed from mildly bullish to sideways. The current technical stance is neutral, with a mix of indicators reflecting varying strengths. The weekly MACD is mildly bearish, while the monthly MACD is mildly bullish. However, Bollinger Bands and KST are bearish on both weekly and monthly time frames, and the Dow Theory and OBV are also mildly bearish. The daily moving averages indicate a mildly bullish stance. In terms of performance, the stock has underperformed the S&P 500 over the past week and month, with returns of -5.86% and -9.13%, respectively, compared to the S&P 500's gains of 1.05% and 2.33%. Over the past year, the stock has slightly outperformed the S&P 500, returning 17.42% versus 17.14%.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

761.35 k

Shareholding (Sep 2025)

FII

1.59%

Held by 5 FIIs

DII

95.12%

Held by 4 DIIs

Promoter

0.00%

How big is Immix Biopharma, Inc.?

22-Jun-2025

As of Jun 18, Immix Biopharma, Inc. has a market capitalization of 63.56 million, classifying it as a Micro Cap company, with net sales of 0.00 million and a net profit of -20.91 million over the last four quarters. The company reported shareholder's funds of 13.25 million and total assets of 22.95 million as of Dec 24.

View full answer

What does Immix Biopharma, Inc. do?

22-Jun-2025

Immix Biopharma, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, currently reporting a net profit loss of $5 million and a market cap of $63.56 million. Key metrics include a negative P/E ratio, no dividend yield, and a return on equity of -217.96%.

View full answer

Is Immix Biopharma, Inc. technically bullish or bearish?

20-Sep-2025

As of September 12, 2025, Immix Biopharma, Inc. shows a neutral technical trend with mixed indicators, underperforming the S&P 500 recently but slightly outperforming it over the past year.

View full answer

Compare Immix Biopharma, Inc. with Similar Stocks

Evelo Biosciences, Inc.Alpha Teknova, Inc.Kronos Bio, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 258 Million ()

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-1.91

Return on Equity

-285.09%

Price to Book

31.18

Revenue and Profits:

Net Sales:

(Quarterly Results - Sep 2025)

Net Profit:

-8 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

14.18%

6 Months

15.25%

1 Year

17.69%

2 Years

-18.94%

3 Years

-3.16%

4 Years

-31.62%

5 Years

-37.17%

Immix Biopharma, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

0.00%

EBIT Growth (5y)

-40.27%

EBIT to Interest (avg)

-20.50

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-1.65

Sales to Capital Employed (avg)

Tax Ratio

0.20%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

18.77%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

6.89

EV to EBIT

-2.31

EV to EBITDA

-2.32

EV to Capital Employed

-8.02

EV to Sales

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

-217.96%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bearish

Bullish

RSI

No Signal

Bearish

Bollinger Bands

Bullish

Moving Averages

Bullish (Daily)

KST

Bullish

Dow Theory

Mildly Bullish

Mildly Bearish

OBV

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Sep 2025

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 5 Schemes (3.29%)

Foreign Institutions

Held by 5 Foreign Institutions (1.59%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Sep'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Sep 2025 is 0.00% vs 0.00% in Sep 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Sep 2025 is -7.04% vs -65.12% in Sep 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Sep'25",
        "Sep'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-7.50",
          "val2": "-7.40",
          "chgp": "-1.35%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-7.60",
          "val2": "-7.10",
          "chgp": "-7.04%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -39.10% vs -90.24% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-22.50",
          "val2": "-16.10",
          "chgp": "-39.75%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-21.70",
          "val2": "-15.60",
          "chgp": "-39.10%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Sep'25 - YoY

Sep'25

Sep'24

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-7.50

-7.40

-1.35%

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

-7.60

-7.10

-7.04%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Sep 2025 is 0.00% vs 0.00% in Sep 2024

Consolidated Net Profit

YoY Growth in quarter ended Sep 2025 is -7.04% vs -65.12% in Sep 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-22.50

-16.10

-39.75%

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

-21.70

-15.60

-39.10%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -39.10% vs -90.24% in Dec 2023

All Annual Results

Company CV

About Immix Biopharma, Inc.

Immix Biopharma, Inc.

Pharmaceuticals & Biotechnology

No Details Available.

Company Coordinates

No Company Details Available

Immix Biopharma, Inc.

1Day

52 Week

CASH

FII

DII

Promoter

How big is Immix Biopharma, Inc.?

Watch in Real-Time

What does Immix Biopharma, Inc. do?

Is Immix Biopharma, Inc. technically bullish or bearish?

Compare Immix Biopharma, Inc. with Similar Stocks

MarketsMojo — Loved in India, Now Global

Dashboard

Mojo Parameters

Stock DNA

Total Returns (Price + Dividend)

Risk Adjusted Returns v/s

News

Announcements

Corporate Actions

Quality key factors

Valuation key factors

Technicals key factors

Shareholding Snapshot : Sep 2025

Shareholding Compare (%holding)

Quarterly Results Snapshot (Consolidated) - Sep'25 - YoY

Annual Results Snapshot (Consolidated) - Dec'24

About Immix Biopharma, Inc.

Company Coordinates